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Abstract
Purpose Patients with non-functioning pituitary adenomas
(NFPA), especially women, have increased mortality. The
aim of this study was to investigate whether mortality in
NFPA patients has changed during the last two decades.
Methods This was a nationwide population-based study
including 2795 patients (1502 men, 1293 women) diag-
nosed with NFPA between 1997 and 2011. Patients were
identified and followed in Swedish National Health
Registries. Standardized mortality ratios (SMRs) with
95 % confidence intervals were calculated for three time
periods at first NFPA diagnosis using the general popula-
tion as reference.
Results Mean (±SD) age at NFPA diagnosis was
58.9 ± 16.8 years. Mean (range) follow-up time was 8.3
(0–18) years, resulting in 20,517 patient-years at risk.
Surgical treatment and radiotherapy were used in 53 and
5 %, respectively. The prevalence of hypopituitarism was
64 % during the first time period of diagnosis and then
declined gradually during the study period (P value for
trend \0.0001). The use of pituitary surgery and radio-
therapy remained stable. In women, mortality was
increased for patients diagnosed between 1997 and 2006
but not for those diagnosed between 2007 and 2011. The
SMR in men remained stable throughout the study and did
not differ from the general population. During the last time
period, 2007–2011, the SMR between men and women did
not differ.
Conclusions While mortality in men with NFPA remains
normal and stable during the last two decades, mortality in
women has declined. Decreasing prevalence of pituitary
insufficiency may be a plausible explanation for this pos-
itive development.
Keywords Mortality  Non-functioning pituitary
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Surgery
Introduction
Hypopituitary patients have increased mortality [1–4].
Several factors associated with increased risk have been
suggested such as etiology, inadequate hormone replace-
ment treatment, pituitary radiotherapy, transcranial sur-
gery, and diagnosis of hypopituitarism at young age
[2, 3, 5–7]. Furthermore, women with pituitary insuffi-
ciency have frequently been found to have an increased
mortality compared to men [1, 3, 8].
We have recently demonstrated that patients, particu-
larly women, with non-functioning pituitary adenoma
(NFPA), have an increased mortality compared to the
background population [5]. We have also shown that
women with NFPA have a higher incidence of type 2
diabetes mellitus, myocardial infarction, cerebral infarc-
tion, and fractures in comparison to both the general pop-
ulation and to men [9].
In the course of the past two decades substantial pro-
gress has been achieved in terms of diagnosis, treatment,
and surveillance of patients with pituitary insufficiency.
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This includes constantly improving imaging techniques,
establishment of growth hormone as a part of the
replacement therapy regime, and adjustment of the gluco-
corticoid replacement therapy towards a near-physiological
pattern [10–13]. Moreover, the current surgical approaches
for lesions in the pituitary region have also proven more
accurate and less traumatic [14].
A meta-analysis, comparing studies including patients
diagnosed during different time periods, has shown that
patients diagnosed during the 1950s have the highest
mortality ratio, which gradually decreases thereafter [8].
However, whether there is an actual decline in mortality is
difficult to confirm since the studies that were compared
have different inclusion criteria, including patients with
different causes of hypopituitarism that have received
dissimilar treatments. In fact, time trends of mortality in
patients with pituitary diseases have not been studied pre-
viously in a single cohort.
The primary aim of this nationwide study was, therefore,
to analyze whether mortality in patients with NFPA has
changed during the last two decades. We also wanted to
investigate whether mortality in men and women is affec-
ted by the length of the follow-up period (latency periods).
Based on the above mentioned improvements in diagnosis
and treatment of patients with pituitary disorders, we
hypothesized that mortality has decreased over time.
Subjects and methods
Study design
The Swedish National Patient Registry (Patient Registry)
was used to identify patients with NFPA diagnosis in
Sweden. The Patient Registry achieved national coverage
in 1987 and contains information from every patient visit
within the Swedish hospital system. The causes of death
were retrieved from the Swedish National Cause of Death
Registry (Cause of Death Registry), which reached national
coverage in 1952. By using the unique Swedish personal
identification number, an individual patient can be fol-
lowed throughout life in the Swedish National Health
registries. The National Board of Health and Welfare
secures high quality for the Patient Registry and Cause of
Death Registry [15, 16]. To identify patients with NFPA
diagnosis we used a combination of identification criteria
to ensure a high quality in the selection of the patients. The
identification process has been previously described in
detail in two studies when mortality and morbidity in the
Swedish national cohort of patients with NFPA was studied
[5, 9]. Briefly, patients included in the study should either
have been diagnosed with NFPA [International Classifi-
cation of Diseases, 10th revision (ICD-10) code D35.2)] at
a medical/endocrine care unit or at a neurological or
neurosurgical care unit. This method of combined criteria
for identification (both diagnostic codes and department
codes) has previously been shown to result in a high sen-
sitivity and specificity when selecting patients with pitu-
itary diseases in epidemiological research in the Nordic
countries [17, 18]. For the studied cohort of patients, the
internal validation of the identification process resulted in a
positive predictive value of 91 % for the NFPA diagnosis
[5, 9]. Other non-functioning pituitary tumors, mostly
cystic pituitary tumors, were found in 4 % of the patients.
Only 1 % of the patients had a lesion not affecting the sella
region. The validation process has previously been
described in detail [5, 9].
Patients with NFPA were identified in the Patient Reg-
istry from January 1, 1997 (when ICD-10 classification was
implemented in Sweden) to December 31, 2011. The date
of the NFPA diagnosis was also gathered from the Patient
Registry, between January 1, 1987 to December 31, 2011
(including both ICD-9 and ICD-10 classification). All
patients that were first diagnosed with an NFPA before
January 1, 1997 were excluded from the cohort. The time at
risk for the patients with NFPA started on the date of
diagnosis (date of the first registered NFPA diagnosis). The
time at risk, in which patients were studied regarding
mortality, ended on the date of death or at the end of the
study (December 31, 2014). Date of birth, gender, diag-
noses of hypopituitarism, and diabetes insipidus (DI) as
well as pituitary tumor treatments were collected from the
Patient Registry. The degree of hypopituitarism and its
management were not available in the registry. Patients
were divided into three groups depending on the time-pe-
riod of their first diagnosis of NFPA (1997–2001,
2002–2006, and 2007–2011). In the analyses of mortality
ratio for patients with tumor treatment, the time of risk
started on the date of the tumor treatment. Data on mor-
tality in the general population was gathered and analyzed
in the same manner as for the patients.
Ethics
The study was approved by the Regional Ethical Review
Board in Gothenburg, Sweden, and by the National Board
of Health and Welfare, Sweden.
Statistical analysis
Person-years at risk were calculated from study inclusion
to death or end of study and stratified according to gender,
5 year age groups, and 1 year calendar periods. The
expected number of cases for each stratum was calculated
using the general Swedish population as reference. The
observed number of deaths among subjects with NFPA was
compared to those expected in the general population using
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standardized mortality ratios (SMRs). Ninety-five percent
confidence intervals (CIs) were calculated assuming a
Poisson distribution of the observed numbers. Subgroup
analyses for different time-periods of diagnosis, gender,
and treatment were performed. SMRs for non-overlapping
subgroups were compared to each other [19]. To analyze
possible trends and differences in between groups regard-
ing diagnosis of hypopituitarism and DI as well as treat-
ment patterns, Chi-square analyses were used with Linear-
by-Linear Association tests and Pearson tests, respectively.
Finally, the effect of different length of follow-up (different
latency periods: 0–5,[5–10, and[10–18 years), i.e. the
time between date of diagnosis and time of death, on
mortality was analyzed [20]. IBM SPSS (version 21; SPSS
Institute) and STATA/SE (version 12.1; StataCorp) soft-
ware were used for the statistical analyses.
Results
Data from 2473 patients with NFPA were included in the
analysis: 1310 men and 1163 women. The mean (±SD) age
at diagnosis was 58.9 ± 16.8 years. The mean (range)
follow-up time was 8.3 (0–18) years, resulting in a total
patient-years at risk of 20,517 (Table 1). A total of 1303
(53 %) patients had been treated surgically, including 771
(59 %) men and 532 (46 %) women (P\ 0.001). One-
hundred-and-fifteen patients (5 %) had received pituitary
radiotherapy with no significant difference between men
(n = 61; 5 %) and women (n = 54; 5 %). Of 1263 patients
who were diagnosed with hypopituitarism, 795 were men
and 468 women (61 and 40 % of men and women
respectively; P\ 0.001).
Six-hundred-and-seven patients (25 %) were diagnosed
between 1997 and 2001, 881 (36 %) between 2002 and
2006, and 985 (40 %) between 2007 and 2011. The
prevalence of hypopituitarism declined during the three
time periods in both men and women (Table 2). The
prevalence of diabetes insipidus and the use of pituitary
surgery and radiotherapy remained stable during the study
period in both genders.
The overall mortality ratio was increased in women
[SMR 1.37 (95 % CI 1.20–1.56)] but not in men [SMR
1.09 (95 % CI 0.97–1.22)] (Table 3). The overall mortality
ratio was increased in patients diagnosed between 1997 and
2001 as well as between 2002 and 2006 but seemed to
return to normal in those diagnosed between 2007 and
2011 (Fig. 1). In women, the mortality ratio was increased
during the first two time periods but not in those diagnosed
between 2007 and 2011 (Fig. 2). The mortality ratio in men
remained stable throughout all three periods of diagnosis
and did not differ from the general population (Table 3).
During the last time period, 2007–2011, the mortality ratio
did not differ between men and women.
Mortality in men with NFPA in relation to duration of
follow-up time (latency periods) did not differ from the
mortality in the background population (Fig. 3). In women,
in contrast, the mortality was increased during all three
follow-up periods, with SMR being the lowest for the
shortest latency period 0–5 years [1.27 (95 % CI
1.03–1.54)] and the highest for the longest latency period
[10–18 years [1.69 (95 % CI 1.24–2.24)]. The mortality
during the longest latency period ([10–18 years) was
significantly higher for woman compared to men
(P = 0.015).
Table 1 Characteristics of
patients with non-functioning
pituitary adenoma




Mean age at diagnosis, years (range) 58.9 (1–97)
Men, mean ± SD 61.0 ± 15.7
Women, mean ± SD 56.6 ± 17.7
Diagnosed with hypopituitarism, n (%) 1263 (51)
Diagnosed with diabetes insipidus, n (%) 122 (4.9)
Mean patient-years at risk per patient, year (range) 8.3 (0–18)





Treated with surgery, n (%) 1303 (53)
Treated with radiotherapy, n (%) 115 (5)
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Discussion
In this study we present the first analysis of time trends of
mortality in patients with NFPA. The overall mortality rate
in women was higher than in the general population as well
as compared to men with NFPA. Interestingly, and in
accordance with our hypothesis, the mortality has
decreased significantly in women who were diagnosed with
NFPA during the most recent time period. In fact, the
mortality in women during the last time period of diagnosis
(2007–2011) was similar with that in men with NFPA, as
well as not different compared to the mortality in the
general population.
There may be several explanations for our results
showing declining mortality in women with NFPA. As we
and others have previously shown, patients with pituitary
hypopituitarism, especially women, have increased mor-
tality [1, 3, 5, 8]. We have recently also demonstrated
increased incidence of myocardial and cerebral infarction
in women with hypopituitarism due to NFPA as compared
to women without hormonal deficiencies [9]. In the current
study a declining prevalence of hypopituitarism was
observed. Half of the women diagnosed with NFPA during
the first time period had hypopituitarism, 42 % during the
second period, and one-third during the last period. Thus, a
plausible explanation for the declining mortality may be
the lower prevalence of pituitary insufficiency due to the
development of more accurate and less traumatic surgical
techniques.
The repetitive finding that mortality in women with
pituitary disorders is higher than in men is worrisome.
Since hypopituitarism was more prevalent in men than in
women, one might speculate whether women are more
rarely tested, and subsequently treated, for growth hormone
deficiency and hypogonadism. Also, the clear difference in
the frequency of pituitary surgery between the genders may
indicate that the women receive a less directed, and inap-
propriate, tumor treatment. It is well known that women
with coronary heart disease are diagnosed later, undergo
more seldom coronary artery surgery, and have worse
outcome than men [21, 22]. Similar gender differences
have been observed concerning diagnosis, morbidity, and
mortality in patients with diabetes mellitus [23]. It is
therefore probable that inferior treatment and surveillance,
may at least contribute, to the worse outcome in women
with NFPA.
An interesting finding in the current study was the
gradually increasing mortality in women in relation to
increasing duration of the follow-up time. A likely expla-
nation is the protracted and cumulative effect of underuse
and/or inadequate hormone replacement therapy in women
with hypopituitarism. This finding also emphasizes the
importance of a sufficiently long follow-up time in epi-
demiological research in general.
Table 2 Hypopituitarism, diabetes insipidus, and treatment with pituitary surgery and radiotherapy in patients with non-functioning pituitary
adenoma in Sweden followed between 1997 and 2014










Total 28 (4.6) 52 (5.9) 35 (3.6) 0.20
Men 12 (3.8) 31 (6.8) 18 (3.4) 0.51
Women 16 (5.5) 21 (5.0) 17 (3.8) 0.29
Surgery
Total 313 (52) 479 (54) 511 (52) 0.96
Men 176 (56) 281 (61) 314 (59) 0.55
Women 137 (47) 198 (47) 197 (44) 0.37
Hypopituitarism
Total 390 (64) 466 (53) 407 (41) \0.0001
Men 242 (77) 289 (63) 264 (49) \0.0001
Women 148 (51) 177 (42) 143 (32) \0.0001
Diabetes insipidus
Total 31 (5.1) 50 (5.7) 41 (4.2) 0.32
Men 15 (4.7) 17 (3.7) 16 (3.0) 0.19
Women 16 (5.5) 33 (7.8) 25 (5.6) 0.88
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Table 3 Time trends of mortality in patients with non-functioning pituitary adenoma in Sweden followed between 1997 and 2014
Outcome Expected no. of deaths Observed no. of deaths Standardized mortality ratio (95 % CI) P value
Overall mortality
Mena 293.4 320 1.09 (0.97–1.22) 0.13
Womena 168.1 230 1.37 (1.20–1.55) \0.0001
Time trends depending on year of diagnosis
Overall
1997–2001 187.8 217 1.16 (1.01–1.32) 0.040
2002–2006 167.7 213 1.27 (1.11–1.45) 0.0009
2007–2011 106.0 120 1.13 (0.94–1.35) 0.19
Men
1997–2001 114.1 117 1.03 (0.85–1.23) 0.81
2002–2006 107.7 123 1.14 (0.95–1.36) 0.16
2007–2011 71.6 80 1.12 (0.89–1.39) 0.35
Women
1997–2001 73.7 100 1.36 (1.10–1.65) 0.004
2002–2006 60.0 90 1.50 (1.21–1.84) 0.0004
2007–2011 34.4 40 1.16 (0.83–1.58) 0.38
Patients treated with surgery
1997–2001 86.5 100 1.16 (0.94–1.41) 0.17
2002–2006 85.1 102 1.20 (0.98–1.45) 0.082
2007–2011 42.9 42 0.98 (0.71–1.32) 0.97
Patients treated with radiotherapy
1997–2001 3.1 13 4.19 (2.23–7.16) \0.0001
2002–2006 5.8 16 2.76 (1.58–4.48) 0.007
2007–2011 2.5 13 5.22 (2.78–8.93) \0.0001
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Fig. 1 Overall mortality in patients with non-functioning pituitary




































Time period for diagnosis
Fig. 2 Overall mortality in women with non-functioning pituitary
adenoma in Sweden followed between 1997 and 2014. **P\ 0.01;
***P\ 0.001
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The prevalence of pituitary adenomas diagnosed post
mortem is around 10 % [24]. In unselected populations the
prevalence of pituitary incidentaloma, i.e. adenomas diag-
nosed accidentally on imaging, range between 10 and 38 %
[25]. In the current study, improved imaging techniques
during the last two decades may have resulted in an
increased incidence of small pituitary incidentalomas, i.e.
tumors that have a minimal influence on health in general.
The unchanged frequency of pituitary surgery and radio-
therapy during the study, however, argues against this
possible explanation. Nevertheless, the lack of information
on tumor size in our cohort is a limitation that must be
taken into account as a possible confounder.
The major strength of this study is the large number of
patients, in fact the largest cohort of NFPA patients studied
to date, and the long follow-up period. Additionally, after a
validation of the diagnosis more than 90 % had a proven
NFPA, which is a high proportion in an epidemiological
study [5]. This study has, however, some limitations. Since
this is a register-based study, detailed information on the
diagnosis and treatment of pituitary insufficiency was not
available. Analysis of time trends concerning prevalence
and treatment of growth hormone deficiency, adrenal
insufficiency, hypothyroidism, and hypogonadism were
therefore not possible. Similarly, detailed information on
pituitary surgery techniques was not available. Also, a
potential bias in the latency period analysis could be that
only patients diagnosed in the earliest period of the study
(1997–2001) have an extensive duration of follow-up.
Nevertheless, male patients do not display the same trend
of increased mortality as women do, which argues against
the influence of this potential bias.
In conclusion, while mortality in men with NFPA
remains normal and stable during the last two decades,
mortality in women has declined. Decreasing prevalence of
pituitary insufficiency may be a plausible explanation for
this positive development.
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